Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform

Eur Urol. 2016 Dec;70(6):906-908. doi: 10.1016/j.eururo.2016.07.015. Epub 2016 Jul 19.

Abstract

Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.

Trial registration: ClinicalTrials.gov NCT00268476.

Publication types

  • Editorial

MeSH terms

  • Androgen Antagonists / adverse effects
  • Androgen Antagonists / therapeutic use*
  • Drug Repositioning
  • Drug Therapy, Combination
  • Humans
  • Hyperglycemia / chemically induced
  • Hyperglycemia / prevention & control*
  • Hypoglycemic Agents / therapeutic use*
  • Male
  • Metformin / therapeutic use*
  • Neoplasm Metastasis
  • Orchiectomy / adverse effects
  • Orchiectomy / methods*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*

Substances

  • Androgen Antagonists
  • Hypoglycemic Agents
  • Metformin

Associated data

  • ClinicalTrials.gov/NCT00268476